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statistical methods that have been devised
(Zuhrie (1978) presented trends with time in
estimated median survival at the last MRC
Leukaemia Reviewmeeting) fortheanalysisof
survivorship in the series of studies from
which the above example was drawn. I am
concerned that correct statistical methodology
should be applied to these data, as they
probably represent the largest immuno-
therapy study at any one British hospital.
When analysing survival data from clinical
trials, it is usually unwise to depart from the
standard statistical methods of logrank P-
values and Kaplan-Meier life-tables (as
described, for example, in Br. J. Cancer
(1977) 35, 1) unless expert statistical guidance
is available to avoid misleading inferences
being drawn. The accepted definition of the
"logrank" and "life-table" methods does not
allow survivors to be ignored.
18 July 1978
R. PETO
Department of the Regius
Professor of Medicine,
Radcliffe Infirmary,
Oxford.
SIR.-We have read Mr Peto's letter and
his earlier comments on the manuscript
of our paper (Harris etal. (1978) Br.J. Cancer,
37, 282), which had led to its extensive
revision. Logrank analysis as recommended
by Peto et al. (1977) (Br. J. Cancer, 35, 1) has
been used throughout the paper, and also for
the data used in the lecture given by one of
us (SRZ) at the 1978 MRC Leukaemia
Review meeting. Mr Peto's objections are to
our additional analyses, notably ofrelapse-to-
death times in Manchester Trial 2. These were
acknowledged in our paper, and the data were
made available in full in the appendix.
In view of Mr Peto's comments, it is worth
reiterating our reasons for analysing "re-
lapse-to-death" separately, even though stati-
stical opinions are divided. Essentially, this
eliminated from the analysis those patients
whose atypically long survival might be due
largely to factors other than treatment. We
(Freeman et al. (1973) Br. Med. J., iv, 571;
Harris et al. (1978) Br. J. Canicer, 37, 282)
have reported that the Manchester AML
Immunotherapy Trials have been associated
with unusually easy induction of second and
subsequent remissions, so that in contrast to
experience in other trials, survival following
first relapse is an important part of the
natural history of AML in Manchester.
Secondly, we and others (reviewed by
Harris et al., (1978) Br. Med. Bull. in press)
have observed that in patients with AML
the probability of entering remission and of
prolonged survival are associated with HLA-
type. Consequently, the "tails" or plateaux
of AML survival curves include an excess of
patients with resistance genes related to
HLA. AML patients at the onset of their
disease thus make up a heterogeneous
population, some sub-sets of which are more
likely to become long survivors than others.
These observations expose the fundamental
fallacies of randomized trials of indifferent
treatment protocols for rare fatal diseases like
AML. Inevitably, small numbers mean that
each treatment arm will contain different
proportions of patients with inherently good
or bad prognosis in relation to the form of
treatment that they receive. Genetically
determined differences in patients' resistance
may greatly exceed the minor differences to
be expected from poor treatment protocols.
The otherwise excellent logrank method
advocated by Peto cannot compensate for
unrecognizedpatientheterogeneity,andfuture
trials should be organized to test the hypo-
thesis that treatment should be tailored to
suit genotype. Finally, statistical nuance
may become much less important when
adequate treatment for AML is available.
28 July 1978
R. HARRIS
S. R. ZUHRIE
Department of Medical Genetics,
St Mary's Hospital,
Manchester.